Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Dynavax Technologies Corporation (DVAX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Dynavax's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
11.690 -0.150    -1.27%
31/12 - Closed. Currency in USD ( Disclaimer )
After Hours
11.990
+0.300
+2.566%
19:59:46 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,875,765
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 11.555 - 11.860
Dynavax 11.690 -0.150 -1.27%

NASDAQ:DVAX Financials

 
A brief overview of the NASDAQ:DVAX financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Dynavax over time.

Dynavax Technologies Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 232.28 million compared to USD 722.68 million a year ago. Net loss was USD 6.39 million compared to net income of USD 293.16 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to basic earnings per share from continuing operations of USD 2.32 a year ago. Diluted loss per share from continuing operations was USD 0.05 compared to diluted earnings per share from continuing operations of USD 1.97 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

DVAX Income Statement

Gross margin TTM 55.88%
Operating margin TTM -13.11%
Net Profit margin TTM -2.75%
Return on Investment TTM -3.05%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 55.6 69.51 60.25 46.92
Gross Profit 1.35 53.95 34.31 18.61
Operating Income -6.5 6.11 -1.41 -28.65
Net Income 0.219 14.29 3.43 -24.33

DVAX Balance Sheet

Quick Ratio MRQ 12.61
Current Ratio MRQ 13.81
LT Debt to Equity MRQ 35.8%
Total Debt to Equity MRQ 41.3%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 997.1 972.93 936.43 969.92
Total Liabilities 375.02 368.02 359.23 406.19
Total Equity 622.07 604.92 577.2 563.73

DVAX Cash Flow Statement

Cash Flow/Share TTM 0.78
Revenue/Share TTM 1.8
Operating Cash Flow  22.14%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 13.77 31.13 28.05 27.62
Cash From Investing Activities -20.24 -106.07 24.72 -52.33
Cash From Financing Activities 1.78 2.99 -0.294 -3.09
Net Change in Cash -4.22 -72.26 52.47 -27.65
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DVAX Comments

Write your thoughts about Dynavax Technologies Corporation
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
David Lawton
David Lawton Aug 04, 2022 3:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
broke thru key resistance. pulled back and successfully tested it. now should bounce off of it a bit today. 1 month target of 20 but could be significantly faster
Ser hh
Ser hh Aug 04, 2022 3:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm watching this stock too but my price target is the 5y low of $1.8. That and only that will be a buy for me.
Ja Ni
Ja Ni Jan 06, 2022 3:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🤣💥🚀💫🤣
LUCIANO GIUDICE
LUCIANO GIUDICE Nov 05, 2021 7:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy the dips
LUCIANO GIUDICE
LUCIANO GIUDICE Nov 05, 2021 7:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
More than 400million vaccine doses via Clover Pharma sold to Cepi, More to come from Valneva, WHO will buy more....stable vaccine and Dynavax Adjuvant stable at room temperature for a month or more.
Dassmond Lim
Dassmond Lim Nov 05, 2021 7:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
totally rely on Heplisav-B for hepatitis B now.
Dassmond Lim
Dassmond Lim Nov 05, 2021 7:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19
Dassmond Lim
Dassmond Lim Oct 01, 2021 2:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
no more story for covid 19. run. personal opinion
Dassmond Lim
Dassmond Lim Oct 01, 2021 12:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
run.seems oledi earn. dun be surprise if .....another -15% dumping on monday.
Dassmond Lim
Dassmond Lim Sep 29, 2021 2:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
as predicted.20
Hold This Sheet
Hold This Sheet Sep 23, 2021 2:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Valneva
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email